Compass Therapeutics (NASDAQ:CMPX) Given Buy Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX) in a report released on Monday,Benzinga reports. They currently have a $10.00 price target on the stock. HC Wainwright also issued estimates for Compass Therapeutics’ FY2028 earnings at $0.94 EPS.

Several other brokerages have also weighed in on CMPX. Wedbush reiterated an “outperform” rating and set a $8.00 price objective on shares of Compass Therapeutics in a report on Wednesday, August 7th. LADENBURG THALM/SH SH raised Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price target on the stock in a research note on Monday, September 16th.

Compass Therapeutics Stock Performance

Shares of CMPX stock opened at $1.59 on Monday. Compass Therapeutics has a fifty-two week low of $0.77 and a fifty-two week high of $2.34. The stock has a 50 day simple moving average of $1.75 and a two-hundred day simple moving average of $1.42. The company has a market cap of $218.77 million, a P/E ratio of -4.47 and a beta of 0.92.

Compass Therapeutics (NASDAQ:CMPX) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.03. On average, research analysts predict that Compass Therapeutics will post -0.42 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its position in shares of Compass Therapeutics by 1.7% during the first quarter. Vanguard Group Inc. now owns 4,152,197 shares of the company’s stock worth $8,221,000 after acquiring an additional 71,008 shares in the last quarter. Opaleye Management Inc. bought a new stake in Compass Therapeutics during the 1st quarter worth approximately $6,277,000. CM Management LLC raised its stake in shares of Compass Therapeutics by 148.0% in the first quarter. CM Management LLC now owns 310,000 shares of the company’s stock worth $614,000 after purchasing an additional 185,000 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Compass Therapeutics by 12.4% in the second quarter. Bank of New York Mellon Corp now owns 283,938 shares of the company’s stock valued at $284,000 after purchasing an additional 31,433 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its position in shares of Compass Therapeutics by 99.7% during the second quarter. Renaissance Technologies LLC now owns 140,600 shares of the company’s stock valued at $141,000 after buying an additional 70,200 shares during the last quarter. Institutional investors and hedge funds own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.